A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)

Inclusion Criteria:

The key inclusion criteria include but are not limited to the following:

• Has histologically or cytologically confirmed advanced/metastatic solid tumor bypathology report who have experienced disease progression on or after prioranti-cancer treatments, or been intolerant to, or refused all treatment known toconfer clinical benefit

• Has head and neck squamous cell carcinoma (HNSCC), melanoma (cutaneous), non-smallcell lung cancer (NSCLC), cervical cancer, triple negative breast cancer (TNBC),urothelial carcinoma (UC), or renal cell carcinoma (RCC; clear cell, papillary)

• If human immunodeficiency virus (HIV) infected, must have well controlled HIV onantiretroviral therapy (ART)

• Has normal cardiac function

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

• If HIV-infected with a history of Kaposi's sarcoma and/or Multicentric Castleman'sDisease

• Has known additional malignancy that is progressing or has required active treatmentwithin the past 2 years

• Has known active central nervous system (CNS) metastases and/or carcinomatousmeningitis

• Has active autoimmune disease that has required systemic treatment in the past 2years except replacement therapy

• Has history of (noninfectious) pneumonitis/interstitial lung disease that requiredsteroids

• Has current pneumonitis/interstitial lung disease

• Has active infection requiring systemic therapy

• Has known history of Hepatitis B (defined as Hepatitis B surface antigen reactive)or known active Hepatitis C virus infection

• Has had an allogeneic tissue/solid organ transplant in the last 5 years